Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
about
Ghrelin for the management of cachexia associated with cancerIs there an effect of ghrelin/ghrelin analogs on cancer? A systematic reviewCachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspectiveThe last days of life: symptom burden and impact on nutrition and hydration in cancer patientsUnderstanding cachexia as a cancer metabolism syndromeMechanisms of metabolic dysfunction in cancer-associated cachexiaTwo ghrelin receptor agonists for adults with malnutrition: a systematic review and meta-analysisThe diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives.Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal study.Therapeutic Potential of Targeting the Ghrelin Pathway.Use of ghrelin in cachexia syndrome: a systematic review of clinical trials.An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin.Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference.Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced AppetiteCancer anorexia: hypothalamic activity and its association with inflammation and appetite-regulating peptides in lung cancer.From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation.Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult Beagle dogs.Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.Pharmacologic Options for the Treatment of Sarcopenia.The wasting continuum in heart failure: from sarcopenia to cachexia.Advances in pharmacologic strategies for cancer cachexia.Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.Cancer-induced muscle wasting: latest findings in prevention and treatment.Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.Validation of the Chinese version of functional assessment of anorexia-cachexia therapy (FAACT) scale for measuring quality of life in cancer patients with cachexia.Novel therapeutic options for cachexia and sarcopenia.Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin.Update on Management of Cancer-Related Cachexia.The Neurobiological Impact of Ghrelin Suppression after Oesophagectomy.Oncology Update: Anamorelin.Atractylodin Induces Myosin Light Chain Phosphorylation and Promotes Gastric Emptying through Ghrelin Receptor.Cachexia: looking yet not seeing.Novel mechanism of ghrelin therapy for cachexia.Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia.Pyrrolidine Dithiocarbamate (PDTC) Attenuates Cancer Cachexia by Affecting Muscle Atrophy and Fat Lipolysis.Sex Differences in Muscle Wasting.
P2860
Q26471773-89E743C0-222F-4EAF-BCA5-2A62D9453FF2Q26739709-24A98FDB-A127-45FF-BC6C-D9502CD36A26Q26749418-F85BFFA3-81CD-4808-A14F-20713EB2E9DAQ26778194-1DA54FDE-3624-40D8-BFC6-7BF469DECFFBQ28069390-3CD613F9-5F30-48D1-BDB5-AC60F8EC6F31Q28079213-F5FBCA82-31BB-4DC0-992A-EB8683EF2992Q28079897-9A15859C-FC5D-4C27-AF5D-52B7F645C145Q30984546-6CA80785-4BB3-47B1-A64C-AB587BD66F55Q33612688-CC4057BD-2921-4881-8717-13C7F039F104Q33624632-90232530-8201-4F64-B2CA-616F287D1D2EQ36165843-752C6053-3D2A-4244-97E5-49CDCBB88DAFQ36311252-BBB32AB2-DD95-4637-932A-3F6766C1C88AQ36706618-9FCE80E7-8F1A-4766-9880-AA2A9BF60A31Q37030111-44721E46-F730-4209-A058-084F5A35A62CQ37030118-AC484017-A248-4B72-B204-CBCE77C0006FQ37057905-B9EB580B-42B5-42D2-B1C0-01652B646C93Q37422775-98AA6F49-8F3F-4357-AAA4-F3D479738EC4Q37667500-48432883-466C-4A7E-B799-B5FB3A7F4B89Q37690695-7CD412DE-8E22-4C50-B8A2-9E3B403D4A68Q38436118-67BEA3E0-219B-4792-A00B-C37F9EE59A81Q38462047-B1467A09-8E3C-4102-A659-A8C780CCBB5CQ38534875-7A4B1DDD-7362-49D0-9F61-BFE9FE385203Q38564746-0EEAC52B-55EF-4335-8812-D947917A05EDQ38578582-1420BB30-A307-426D-ABCB-8E34AFA33874Q38636513-63F282EB-C12A-4675-8372-BEC046293D05Q38670238-2D78924E-F291-49A8-94E0-4D75E51DB927Q38681113-F783AFA7-77C2-4227-AD44-ADBF1AEA0B6BQ38772058-6BC142AF-FDFD-4F7C-9469-88DA77EDAF37Q38789158-73042E7D-456A-469B-8863-30032FE2C15AQ38887581-A4EB7269-C9B1-4766-85AA-2B371ADEA425Q38931233-002D0665-DEAA-4FF6-B988-87D9E3556100Q38990581-A51AAC62-56D9-43EF-8553-F12B50AC0D7CQ39062975-00743DDF-21C7-4F25-9E46-5CFA272CF367Q41511150-D9BF6772-FBDC-4098-B9A6-286D0E1E2840Q41528767-17E9AEAF-D976-4EBE-A117-6CB21BCC1913Q42366311-A5272B21-4CD6-49DB-A3BC-39804F1FF86FQ43142441-71489673-78A2-47E4-B129-61A315D598F7Q46621430-1B092D5D-3013-4EB6-846F-17DAFAC8354DQ47233582-407F2A4F-23E4-4534-B271-F76EE2A71644Q47311543-E58F23CE-4F11-40F5-9B8E-7F23DF94E8A8
P2860
Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Anamorelin for patients with c ...... ntrolled, double-blind trials.
@ast
Anamorelin for patients with c ...... ntrolled, double-blind trials.
@en
type
label
Anamorelin for patients with c ...... ntrolled, double-blind trials.
@ast
Anamorelin for patients with c ...... ntrolled, double-blind trials.
@en
prefLabel
Anamorelin for patients with c ...... ntrolled, double-blind trials.
@ast
Anamorelin for patients with c ...... ntrolled, double-blind trials.
@en
P2093
P1433
P1476
Anamorelin for patients with c ...... ntrolled, double-blind trials.
@en
P2093
Charles D Graham
Elizabeth Manning Duus
John Friend
José M Garcia
Ralph V Boccia
Suzan Allen
P304
P356
10.1016/S1470-2045(14)71154-4
P577
2014-12-16T00:00:00Z